Barclays ADR

BCS shares are up 32.3% YTD as cost cuts, capital redeployment and solid liquidity drive investor optimism. Is now a good buying opportunity?» Mehr auf zacks.com

Two Sigma Investments LP lifted its stake in shares of Traeger, Inc. (NYSE:COOK – Free Report) by 32.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 123,931 shares of the company’s stock after acquiring an additional 30,539 shares during the period. Two Sigma Investments LP owned 0.09% of Traeger worth $296,000 as of its most recent SEC filing. A number of other large investors have also made changes to their positions in the stock. Graham Capital Management L.P. acquired a new stake in Traeger in the 4th quarter worth about $37,000. Two Sigma Securities LLC acquired a new stake in Traeger in the 4th quarter worth about $78,000. Bank of America Corp DE boosted its stake in Traeger by 36.6% in the 4th quarter. Bank of America Corp DE now owns 33,314 shares of the company’s stock worth $80,000 after buying an additional 8,933 shares during the last quarter. Deutsche Bank AG boosted its stake in Traeger by 231.8% in the 4th quarter. Deutsche Bank AG now owns 41,344 shares of the company’s stock worth $99,000 after buying an additional 28,883 shares during the last quarter. Finally, Barclays PLC boosted its stake in Traeger by 15.9% in the 4th quarter. Barclays PLC now owns 51,987 shares of the company’s stock worth $124,000 after buying an additional 7,126 shares during the last quarter. Institutional investors and hedge funds own 46.84% of the company’s stock. Analyst Ratings Changes A number of brokerages have issued reports on COOK. Royal Bank of Canada decreased their price target on Traeger from $2.75 to $2.00 and set a “sector perform” rating on the stock in a research note on Friday, March 7th. Robert W. Baird decreased their price target on Traeger from $3.50 to $2.50 and set a “neutral” rating on the stock in a research note on Friday, March 7th. Telsey Advisory Group decreased their price target on Traeger from $2.50 to $2.00 and set a “market perform” rating on the stock in a research note on Friday, May 2nd. Morgan Stanley cut their price objective on Traeger from $3.00 to $2.50 and set an “underweight” rating on the stock in a report on Friday, March 7th. Finally, Canaccord Genuity Group cut their price objective on Traeger from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, April 29th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Traeger currently has an average rating of “Hold” and a consensus price target of $2.44. Check Out Our Latest Research Report on Traeger Traeger Stock Performance Traeger stock opened at $1.85 on Wednesday. The stock’s 50 day moving average price is $1.45 and its 200 day moving average price is $2.08. The firm has a market capitalization of $251.16 million, a PE ratio of -4.63 and a beta of 1.38. The company has a debt-to-equity ratio of 1.42, a quick ratio of 1.08 and a current ratio of 2.09. Traeger, Inc. has a one year low of $1.28 and a one year high of $3.97. Insider Activity In related news, CEO Jeremy Andrus acquired 250,000 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was purchased at an average cost of $1.38 per share, for a total transaction of $345,000.00. Following the purchase, the chief executive officer now directly owns 14,052,354 shares in the company, valued at $19,392,248.52. This represents a 1.81% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. In the last ninety days, insiders bought 730,387 shares of company stock worth $1,009,986. 14.70% of the stock is currently owned by insiders. Traeger Company Profile (Free Report) Traeger, Inc, together with its subsidiaries, designs, sources, sells, and supports wood pellet fueled barbecue grills for retailers, distributors, and direct to consumers in the United States. Its wood pellet grills are internet of things devices that allow owners to program, monitor, and control their grill through its Traeger app. See Also Five stocks we like better than Traeger Why Are These Companies Considered Blue Chips? AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway What to Know About Investing in Penny Stocks Casey’s Surges on Strong Q4, More Gains Likely Ahead Value Investing: Is it a Good Strategy in 2022? (Hint: Always) Government Mandate Sends eVTOL Stocks Flying Want to see what other hedge funds are holding COOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Traeger, Inc. (NYSE:COOK – Free Report).» Mehr auf defenseworld.net

Squarepoint Ops LLC purchased a new position in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 19,461 shares of the company’s stock, valued at approximately $59,000. A number of other large investors also recently bought and sold shares of the stock. SG Americas Securities LLC raised its stake in TScan Therapeutics by 31.2% during the fourth quarter. SG Americas Securities LLC now owns 20,415 shares of the company’s stock worth $62,000 after purchasing an additional 4,852 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of TScan Therapeutics by 41.1% during the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock valued at $59,000 after acquiring an additional 5,694 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of TScan Therapeutics by 5.2% during the 4th quarter. Wellington Management Group LLP now owns 132,895 shares of the company’s stock valued at $404,000 after acquiring an additional 6,550 shares in the last quarter. Barclays PLC lifted its holdings in shares of TScan Therapeutics by 16.3% during the 4th quarter. Barclays PLC now owns 67,508 shares of the company’s stock valued at $206,000 after acquiring an additional 9,441 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new position in shares of TScan Therapeutics during the 4th quarter valued at $32,000. Hedge funds and other institutional investors own 82.83% of the company’s stock. TScan Therapeutics Price Performance TCRX opened at $1.69 on Wednesday. The company has a 50-day moving average of $1.43 and a 200-day moving average of $2.18. The company has a market capitalization of $95.64 million, a P/E ratio of -1.59 and a beta of 0.98. TScan Therapeutics, Inc. has a 1-year low of $1.02 and a 1-year high of $9.29. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. TScan Therapeutics (NASDAQ:TCRX – Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The business had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.62 million. Equities analysts expect that TScan Therapeutics, Inc. will post -1.12 EPS for the current fiscal year. Analysts Set New Price Targets TCRX has been the topic of several recent research reports. HC Wainwright reduced their target price on shares of TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Wedbush restated an “outperform” rating and set a $7.00 target price on shares of TScan Therapeutics in a report on Tuesday, May 6th. Needham & Company LLC restated a “buy” rating and set a $9.00 target price on shares of TScan Therapeutics in a report on Tuesday, April 8th. Barclays reduced their target price on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $10.00 price target on shares of TScan Therapeutics in a research note on Friday, March 14th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $7.80. View Our Latest Research Report on TCRX Insider Activity at TScan Therapeutics In other news, major shareholder Lynx1 Capital Management Lp bought 1,200,000 shares of TScan Therapeutics stock in a transaction on Tuesday, May 20th. The stock was purchased at an average cost of $1.20 per share, with a total value of $1,440,000.00. Following the purchase, the insider now directly owns 7,946,141 shares of the company’s stock, valued at approximately $9,535,369.20. This trade represents a 17.79% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 4.35% of the company’s stock. TScan Therapeutics Profile (Free Report) TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.» Mehr auf defenseworld.net